Gujarat Themis Biosyn Allots Rs 585 Crore NCDs To Fund MBJ Acquisition

Allotted 58,500 secured unlisted rated NCDs aggregating Rs585cr via private placement — Series1 Rs295cr 60-month 10% p.a. and Series2 Rs290cr 18-month 17.75% p.a., secured with promoter personal guarantee; proceeds for Japan subsidiary to fund MicroBiopharm Japan acquisition and general corporate purposes. Context: locks debt leg for MBJ deal.